Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE AUTOINJECTOR versus PAMINE FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE AUTOINJECTOR versus PAMINE FORTE.
ATROPINE (AUTOINJECTOR) vs PAMINE FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine and other cholinergic agonists.
Anticholinergic agent; competitively blocks acetylcholine at muscarinic receptors, reducing gastrointestinal motility and secretory activity.
2 to 4 mg intramuscularly (lateral thigh) or intravenously, repeated every 10-20 minutes if needed until muscarinic signs abate, maximum 3 doses.
1 tablet (5 mg) orally 4 times daily, before meals and at bedtime.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (adults); prolonged to 6-12 hours in elderly or hepatic impairment.
1.5-2 hours; prolonged in renal impairment
Renal: ~30-50% unchanged; hepatic metabolism: ~50%; fecal: minor.
Renal (70% unchanged), biliary/fecal (30%)
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent